昌吉哪家能做无痛人流昌吉人流手术哪好,昌吉哪里看男科的医院好,昌吉男科医院国营的,昌吉包皮为什么一定要割,昌吉40割包皮,昌吉阴道紧缩术去哪好,昌吉人流哪种最好

BEIJING, Feb. 1 (Xinhua) -- Wu Bangguo, chairman of the Standing Committee of the National People's Congress of China, on Monday sent congratulatory messages to Myanmar's newly-elected upper house speaker U Khin Aung Myint and lower house speaker Thura U Shwe Mann, respectively,on their taking offices.Myanmar's house of nationalities (upper house) session on Monday elected U Khin Aung Myint, Minister of Culture, as speaker of the upper house.Also on Monday, No. 3 Myanmar state leader Thura U Shwe Mann, who is a member of the State Peace and Development Council and previously the Chief of General Staff of the army, the navy and the air force, was elected as speaker of the house of representatives by the house of representatives (lower house).

WASHINGTON, April 11 (Xinhua) -- In the first clinical trial of gene therapy for treatment of intractable pain, U.S. researchers from the University of Michigan's Department of Neurology observed that the treatment appears to be able to provide substantial pain relief.In a study published online in the Annals of Neurology and seen on Monday, the researchers showed that the novel agent NP2 is safe and well-tolerated. In addition, measures of pain in the treated patients suggested that NP2 may provide a substantial analgesic effect.NP2 is a gene transfer vector that expresses the naturally- occurring opioid peptide enkephalin. In preclinical work in animals, David Fink, chair of the Department of Neurology, and his coworkers had demonstrated that injection of NP2 into the skin reduces pain in models of pain caused by nerve damage, inflammation or cancer.In the clinical trial, 10 patients with unrelenting pain caused by cancer were injected with the gene transfer agent in the area of skin related to the location of pain."The concept underlying this therapeutic approach is that injection of NP2 into the skin results in uptake into the nervous system and the production and release of a pain-relieving chemical in a controlled site in the pain pathway," says Fink. "In the study, patients who received the low dose of vector showed little reduction in pain; patients receiving the higher doses showed a greater than 80 percent reduction in pain over the course of four weeks following treatment."Fink's laboratory has been working on the use of modified herpes simplex virus-based vectors that are taken up by sensory nerves following skin injection to develop therapies for diseases of the nervous system for more than 20 years. Patents related to this technology have been exclusively licensed by Diamyd Medical, a publicly-traded Swedish biotechnology company that sponsored the trial, and the human-grade vector NP2 was produced by Diamyd, Inc, the U.S. subsidiary of Diamyd Medical.A phase 2 trial to compare NP2 to a placebo control has already been initiated under sponsorship from Diamyd.

BEIJING, March 24 (Xinhuanet) -- A new study has found that Actos, a medicine treats onset diabetes, could also reduce the diabetes risk in people with prediabetes.The study, which was published Wednesday in New England Journal of Medicine, followed 602 prediabetics whose obesity, ethnicity, family history and other factors put them at high risk of developing diabetes.The research findings showed that Actos, generically known as pioglitazone, reduced the odds of developing Type 2 diabetes by 72 percent in people with prediabetes.Only 2.1 percent of those who took Actos developed diabetes each year over the three years of the study, compared with 7.6 percent of those who took a placebo.Lead author of the study Ralph DeFronzo said, "The 72 percent reduction is the largest decrease in the conversion rate of pre-diabetes to (Type 2) diabetes that has ever been demonstrated by any intervention, be it diet, exercise or medication."However, Actos can have significant side effects, including water retention, moderate weight gain, and increased risk of bone fractures.

WASHINGTON, April 11 (Xinhua) -- Taking a statin before having major elective surgery reduces potentially serious kidney complications, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.Each year, more than 230 million major elective surgeries are performed around the world. Unfortunately, many patients who undergo major operations develop kidney injury soon after surgery, often due to decreased blood flow to the kidneys and/or the effects of inflammation.Animal studies suggest that the cholesterol-lowering drugs called statins protect the kidneys from such damage, but whether a similar benefit occurs in humans is uncertain. To investigate, Amber Molnar, University of Western Ontario, and colleagues conducted a population-based retrospective study of all older patients who underwent major elective surgery in the province of Ontario, Canada from 1995 to 2008. Surgeries included cardiac, thoracic, vascular, intra-abdominal, and retroperitoneal procedures.A total of 213,347 patients from 211 hospitals underwent major elective surgery, and 4,020 patients (1.9 percent) developed postoperative kidney injury within two weeks of surgery. A total of 1,173 patients (0.5 percent) required dialysis within two weeks of surgery, and 5,974 patients (2.8 percent) died within a month of surgery.Prior to surgery, 67,941 patients (32 percent) were taking a statin. Patients taking a statin were 20 percent less likely to develop kidney injury, need dialysis, and die compared to patients who were not taking a statin. Also, there was evidence of a dose-effect, with patients on higher potency statins having less kidney injury. In addition, statins were beneficial whether they were started greater than 90 days or less than 30 days prior to surgery."Our study suggests that statin use in older persons results in less kidney injury following major elective surgery and reduces the risk of premature death after surgery," said Molnar, adding that the results warrant further investigation with more rigorous studies, but such trials will be difficult to carry out.

BEIJING, March 17 (Xinhuanet) -- A new study has shown that gene therapy can reduce symptoms in patients with Parkinson's, media reports said Thursday.The study, published in the journal Lancet Neurology, is the first to show positive results in a test of gene therapy against a sham operation in 45 U.S. Parkinson's patients.The treated group showed a 23.1 percent improvement on a scale of Parkinson's symptoms six months after treatment, compared to a 12.7 percent improvement for patients who received sham surgery, according to the published research."Gene therapy is no longer just a theory," said Michael Kaplitt, a neurosurgeon at New York-Presbyterian Hospital and Weill Cornell Medical Center, and one of the study authors. "We are getting much closer to a reality where this treatment can be offered to patients."In patients with Parkinson's disease, their brains get overactive after losing the normal supply of a chemical called GABA. The new treatment, gene therapy, works by inserting billions of copies of a gene into patients' brains that helps them produce more GABA.Kaplitt said the results might spur similar treatments for other brain disorders like Alzheimer's, epilepsy and depression.